Thank We'll turn Slide X. you, to Warren. now
enrollment mentioned, pandemic, Warren the patients' study and to participate to by global in and impact and this CARDINAL becoming Early conducting to our causing in-clinic obtain and the complete in receive efficacy in could safety potential clinical study of caused COVID-XX prior As have affecting of ability spread quarantines it's and clinical our priorities resume the our recognized team Alport globally, visits drug. virus the syndrome are data negative top including FALCON. and maintain a to integrity year, CKD for bardoxolone if trials,
biologics a Closure assessments, are key visits collect procedures. to For COVID-XX to as such to administer the other through presented has many therapies imaging data drugs set of obstacles exams, of infusing efficacy trial sites many and gene or due performing clinical or challenging clinical of necessary studies, for study site studies. sophisticated ongoing
trials, at-home health facility, important at CKD have conduct patients does complete including kidney for to and a small providing to drug medical occasionally our that our is key the and unable used intend that that function, molecule an visit. in-clinic capsules blood-based visits prior if for infused to CARDINAL in is not self-administered home we formulated or a us orally our studies. fortunate of markers nurses visits In are study endpoints to be options trials, CKD were We need efficacy
to CARDINAL that geographies utilized began these including of Europe. nurses have to China, U.S. affected we now relationships with been cases vendors pandemic, in COVID to increase quickly visits the established outside by and their the mobilize our As conduct
The date, health the first approximately occurred March have home in France visit. to XX had patients a Spain U.S., visit home-health and in and
significant no data impact observed this have integrity during We on period.
additional patients supply dispensed As able sites who receive of also today, visits. sites work of from than vendor the more able half to the scheduled homes able mid-summer. study of ensure supply are have to a last our to with that drug trial patients Phase in months continuity XXX are had treatment. while shipped conducting We drug that patients, to able clinic until the most CARDINAL enrolled were their manufacturing to drug if sufficient study. they to regularly now of is were Typically, directly drug patients' to III supply patients completed were were so ensure pivotal closed. We our their were to supply have We ship to
the continue affected site We of of will to closures are who supply throughout drug by patients homes shipping directly duration the the trial.
to have in sites open, countries in and Japan patients those the During Australia have in-clinic conduct visits. able and been remained pandemic,
if the drug continue use home less direct populated in in supply will trial, the densely regions prepared to trend of continues, health using able to have trial in-clinic Germany described. I remain been the of remainder we hope as the shipment complete visits. to sites sites and this conduct the We needed through but While visits indefinitely, and Spain U.S., closed we're solutions trial recently
turned ADPKD COVID-XX actively a into to Slide bardoxolone enrolling patients of when in Turning X. was trial The FALCON pandemic.
the significant CARDINAL patients are we and For data us process trial, no The These starting patients are in fairly in in we any visits screening same already March who paused sites in previously we who enrollment FALCON integrity. and And including research have trial, to effect home is we and health we already direct screening observed when disclosed, the of implemented supply to close shipment patients' have the were homes. to intensive. as to patients. enrolled, procedures trial drug have on allowed continue in solutions that
affected of geographies sites are starting during As were not have have by the and Europe been COVID-XX, to our and previously I some closed CARDINAL some U.S. now remained open, sites rural reopen. some mentioned the in that discussion,
communicating sites FALCON are and to planning screening We soon. restart have our with been
their decisions make basis, to a will on patients. site-by-site on capabilities safely individual screen based We and enroll
can As hopeful screening that Warren begin patient quarter. this said, we are
to Moving Slide X.
Transplant addition in NDA European trial and upcoming and congress, to preparations, abstracts new publish programs. known and In accepted Dialysis taking X from ERA-EDTA, also lead virtually present and collaborators as Association, presentation European early our execution international at its we our place for continuing our us data and June. Renal Association to are has The on
activation trial, proteinuria. a of of and poster effects These pancreas hallmarks of our are the MOXie kidney patients, study FA has cord, is transplant protein, mutations meeting impaired have CKD, MOXie patients this include a of patients pathways. very FA mitochondrial to the Clinically, ERA-EDTA the trial, function uncommon globally have know, such disease pressure blood year. is you assess lead In disease. do Kidney by studied FA of not spinal over these abstracts in brain, high kidney a production for mitochondrial course that dialysis of omaveloxolone attended mitochondrial including been factors inflammatory the organs Ataxia. well and frataxin, conference the because caused And kidney risk is disease liver. second entitled European pivotal in these or as not we energy and rare been function best many progression in patients in or The Friedreich's requiring effects nephrology dysfunction accepted of of FA in several patients dysfunction. in with a end-stage major called in heart, kidney a prospectively part studied, traditional the As year. in
mL/min higher CKD less that placebo In X.X was lose observed disease, nephropathy, ADPKD, first of the MOXie on was mL/min. loss highly After are pediatric And forms and IgA FA progressive. and the loss average considered other to function. eGFR that in patients XX.X XX have kidney average, progressive data mL/min. of more of eGFR decrease in weeks neurological than are X.X many diabetics, of X.X mean CKD what CKD Our the rapidly who rapidly mL/min. patients, have overall patients hypertensives, is contemporary it trials is than The of severe for of patients progressive show forms of for FSGS treatment,
As progression CKD. in risk trial mentioned, patients MOXie in our without factors traditional this loss occurred of for
disease, most patients. enough kidney to have importance patients survive the to CKD. will FA clinical role the not dysfunction long reach FA does, the of It unfortunately, Because however, highlight end-stage mitochondrial in this finding of management does of not relevance direct
distinct be to of context have development thought As now CKD, for many have activation forms critical several pathways. mitochondrial very final caused across observed pathogenesis production inflammatory the of ultimately progression pathway insults of by by lead we impaired forms in to a function bardoxolone, extensively in of metabolism, characterized that the common different and and been of CKD, discussed of the impairments energy of are
clinical studies form pure In a with key biopsy persuasive addition of patients to most of mitochondrial view, that in have of regulators that kidney data our human function. mitochondria the from patients we evidence are, are cited, CKD these disease
that the Beyond demonstrate bardoxolone, placebo-corrected the We assessed improvement as also patients, XX.X part likely also the XX.X the XX mL/min kidney function eGFR. not conceptual of the slowed insights function. had on-treatment The demonstrating function, but and kidney it patients. can XX a discontinued this eGFR And pediatric that X.X of conducted week kidney improved days safety was we in change a at these at visit At mL/min, week across was omav kidney off-treatment improve mL/min. drug, all structural higher data washout omav, was they provide, only magnitude XX, in omav visit, that dynamically after placebo-corrected and on after fibrosis. like effect patients
CODE, a program ongoing presenting KIDNEY a with genetic which testing medical be also for affairs patients important of disease, we'll ERA-EDTA, aspect chronic At entitled kidney describes our an activities. poster
of basis As CKD. are recent genetic a partnership help CODE of an which nephrologists in sponsoring forms Invitae the This testing suggests program, patients see is genetic underlying we of in on with XX% recognition can KIDNEY cause. Slide various identify X, launched of initiative that with CKD was approximately literature, you genetic to have
is has patients helpful suggest recent a a syndrome to number Further, with are receiving known undiagnosed form large of not treatment correctly, may misdiagnosed either actual the with may diagnosed CKD, one's Alport of or it of other second CKD. forms who And to be than patients Alport not their that CKD. relevant be are or common common hereditary syndrome of be While been data thought. form more most
Blood consists including test and are saliva in to from a time. mutation interest It Alport kit and panel syndrome, certain most linked broad be turnaround XX rapid common which and saliva nephrology receives others, U.S. data the can that directly a a or demographics can a community. of where of ADPKD, The CKD, visit, to ordering of provides FSGS the to has shipped causes position. de-identified Reata available results, during be genes hereditary the a is including patients collected patient's clinic that home.
of that of In the first time and is have of the to tests half of and have hypertensive had have These previously is can that these that uptake CKD, IgA for to considered have test been access, the several generally the phase, and misdiagnosed FSGS, rapid feedback several easy test ADPKD, positive were received easy clinical has forms order, other diagnoses months pilot to nephropathy benign. patients and the interpret. nephrology syndrome, we include turnaround approximately excellent in that be the we very half CKD. results with been positive Alport Of community
care these they While are may the of usually patients nephrologist, care. be incorrect a receiving under
be should syndrome medicine which to would For receive care for or which action. IgA or nephropathy. patients precision typically with patient These data patients, ADPKD their tolvaptan to not nephrologists and in given instance, an allow Alport diagnose is appropriately immunosuppressants,
be his clinical identify Importantly, Alport not investigators used from straightforward with we that who yet syndrome prior criteria X of Based is one to have diagnosed straightforward. identifying on can patients. learned are syndrome or Alport our and literature CARDINAL misdiagnosed colleagues, patients
the haven't patient Alport of patients blood X have normal; in We using presence eGFR been of a prospectively CKD below these to all urine, defined with history have program. effective. as hematuria with family shown the that factors of: one, CODE of CKD; syndrome criteria KIDNEY a an XX% three, now risk has in two, or the found and
results call business operations quarter. our the turn and Manmeet for provide to now I'll to financial over of summary a the
